PfizerPFE
$162.2B market capPfizerPFERevenue: is the business selling more than it used to?
$62.6B−2% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $62.6B in 2025, compounding -12% a year since 2022 though the path has been bumpy.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFENet income: how much of that revenue becomes profit?
$7.8B−3% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $7.8B in 2025, compounding -37% a year over three years. Earnings per share moved -60% over the last twelve months. Trailing twelve-month profit stands at $4.3B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEHow fast is it growing, year by year?
-1.6%revenue growth, FY 2025
Off the axis: 2024 earnings +279.0% - rebounds off a collapsed prior year.
→Revenue grew -2% in 2025 against a five-year average of +16%. Earnings fell +3% on top of it. 2024's +279% earnings rebound off a collapsed base sits off the axis.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFERevenue per share: is your slice growing as fast as the company?
$10.95revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-28), not a full fiscal year
→Revenue per share reached $10.95 in 2025, compounding -12% a year - in line with PFE's own -12%, so the share count is not distorting your slice. Free cash flow per share stands at $1.59.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEFree cash flow: what is left in real cash after everything?
$9.1B−8% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $9.1B in 2025, compounding -30% a year since 2022. The trailing twelve months stand at $11.0B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→15 cents of every sales dollar became free cash in 2025, down 14 points since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-28), not a full fiscal year
→The biggest claim on each sales dollar is capital spending, at 4% of revenue (stock compensation 1%). That share has risen since 2022, so the cost of competing is climbing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-28), not a full fiscal year
→Net margin stands at 12% in 2025. PFE doesn't break out gross or operating margin in its filings, so net is the only layer the data supports.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-28), not a full fiscal year
→PFE earns 5% on shareholders' capital. Return on capital employed isn't meaningful for this business model, so ROE carries the picture alone.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEWhat has the market paid for PFE over time?
37.5xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 37.5x earnings, the market is paying +138% more than PFE's own 11-year median of 15.7x. Expectations are elevated, so more has to go right to justify the price.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEWhat cash return does the business throw off per dollar of market value?
6.8%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 6.8% of annual free cash flow, less than its 11-year median of 9.2% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFECould it handle its debt if things went wrong?
◌ 2026 = the latest balance sheet (2026-06-28), not a fiscal year-end
→Debt of $63.2B sits against $976M of cash, or 0.7x shareholders' equity.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEIs the company's own capital growing?
→The company's own capital shrank from $89.0B in 2023 to $85.2B (-4%). Buybacks or losses are drawing the buffer down - the distinction matters.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEHow much goes back, and how much leaks out as stock comp?
→PFE returned no cash to shareholders in the latest filed year: everything is being retained or reinvested.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEHow fast is your ownership being diluted - or concentrated?
→The share count grew 0.2% in 2025. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEPFE has issued or retired shares - did shareholders end up better off?
→PFE has shrunk its share count -27% from 2011 to 2025, so each remaining share owns more of the business. Revenue per share is +41% over the same years.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28
PfizerPFEAre the people running it buying or selling?
→Insiders bought $3M and sold $134,661 on the open market, a net purchase of $3M.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-28